Mannitolo Bioindustria L.I.M

Mannitol, the active ingredient in Mannitolo Bioindustria L.I.M, is an osmotic diuretic presented as a sterile injection solution for intravenous administration. It is used in the European Union to lower intracranial and intraocular pressure, to promote diuresis in acute renal failure, and to aid the excretion of other drugs.

GNH USA supplies Mannitolo Bioindustria L.I.M as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide and supporting patient care through reliable logistics.

Mannitol is an osmotic diuretic used in conditions where fluid shift and pressure reduction are required.

- Intracranial hypertension: lowers intracranial pressure to prevent cerebral edema. - Intraocular hypertension: reduces intraocular pressure in acute glaucoma attacks. - Acute renal failure: promotes diuresis to assist renal clearance. - Drug excretion facilitation: creates an osmotic gradient that enhances elimination of certain nephrotoxic agents.

Mannitol may cause a range of adverse reactions, most of which are related to its osmotic activity and fluid shifts.

Common Side Effects: - Headache: mild to moderate discomfort often reported during infusion. - Nausea or vomiting: gastrointestinal upset due to rapid osmotic changes. - Thirst or dry mouth: sensation of increased plasma osmolality. - Transient electrolyte imbalance: mild hyponatremia or hypokalemia. - Tachycardia: increased heart rate secondary to volume expansion.

Serious or Rare Side Effects: - Pulmonary edema: fluid overload leading to respiratory compromise. - Severe hyponatremia or hypernatremia: dangerous shifts in serum sodium. - Acute renal failure: paradoxical worsening of kidney function. - Anaphylactic reaction: rare hypersensitivity requiring immediate intervention. - Cardiac arrhythmia: electrolyte disturbances precipitating rhythm disorders.

Mannitol requires careful monitoring of fluid balance and electrolyte status.

- Renal impairment: assess kidney function before and during therapy. - Electrolyte disturbances: regularly check serum sodium and potassium levels. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant diuretics: increased risk of dehydration; adjust dosing as needed. - Hyperosmolar states: avoid rapid infusion to prevent sudden shifts in plasma osmolality. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several drug classes, altering fluid and electrolyte balance.

Major Interactions (Avoid): - Loop diuretics: additive diuretic effect may cause severe dehydration. - Insulin: osmotic diuresis can affect glucose control, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance hypotensive response. - Nephrotoxic drugs (e.g., aminoglycosides): monitor renal function closely. - Lithium: osmotic shifts can increase serum lithium concentrations.